The announcement of a pre-NDA meeting indicates progress in the regulatory process and is typically viewed as a positive development for a pharmaceutical company. It suggests that Inhibikase Therapeutics is moving closer to potentially obtaining approval for IkT-001Pro. This news is likely to be seen favorably by investors, potentially leading to a short-term increase in the stock price.